WatchlistSix Spanish biotech startups to watch in 2026The 2025 AseBio Report shows a Spanish biotech ecosystem that is not only expanding, but attracting capital at a new scale: Spain counted 1,119 dedicated biotech companies in 2025, up 10.4% year on year, … more ➔
RegulatoryFDA keeps Newron’s evenamide trial on hold in U.S.Newron Pharmaceuticals will expand its Phase 3 evenamide trial outside the U.S. after the FDA decided to maintain a hold on enrollment at American sites. more ➔
licensingAddex regains rights to addiction drug candidate from IndiviorSwiss biotech Addex Therapeutics has regained global rights to a GABA-B drug portfolio from Indivior, including a candidate for substance use disorders that has completed studies needed before a Phase … more ➔
Drug developmentNovo licenses Nanexa’s long-acting injection platform in €1.165B dealSweden’s Nanexa has granted Novo Nordisk a global license to use its PharmaShell drug delivery technology in up to five programs targeting obesity, type 2 diabetes and other cardiometabolic diseases. … more ➔
AppointmentsBavarian Nordic names new CEO; Abivax and ProQR add key leadersEvery Friday, The Leadership Edit looks at the people taking new roles across European biotech and what their moves may tell us about the companies they join. We’ll follow chief executives, scientific … more ➔
licensingRoche signs two deals worth about $3.5B in one dayRoche signed two research partnerships on Sept. 24: one with Atavistik Bio to discover drugs for cardiovascular, renal and metabolic diseases, and another with Earendil Labs to develop cancer antibodies. … more ➔
innovation policyNine pharma companies urge Europe to invest more in medicinesEuropean biotech and clinical-research figures broadly agree with nine major drugmakers whose chairs signed a letter urging governments to reward new medicines better, but say the fixes go well beyond … more ➔
startupsKasvu raises €30M for depression drug targeting TrkBFinnish biotech Kasvu Therapeutics has raised €30 million in Series A financing to take its lead depression candidate into clinical development, adding to a growing number of European investments in … more ➔
licensingBoehringer pays up to $250M to expand Variant Bio’s pact into heart diseaseBoehringer Ingelheim has expanded its partnership with Variant Bio into cardiovascular disease, adding potential payments exceeding $250 million (€219 million). The agreement builds on a kidney disease … more ➔
fundraisingBasecamp Research raises $140M for AI-designed cell therapiesLondon-based Basecamp Research has raised $140 million (€122 million) in an oversubscribed Series C to expand its biological AI models and move a preclinical therapeutics pipeline toward the clinic. … more ➔
